SCHEMBL2919338

SCHEMBL2919338

COc1cc2ncnc(N3CCN(C(=O)OC(C)(C)C)CC3)c2cc1OS(C)(=O)=O

nearest known ligand 0.64

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.64
BACE1 P56817 2/20 0.64
PDGFRB P09619 13/20 0.61
PDGFRA P16234 4/20 0.57
ENPP1 P22413 3/20 0.56
AURKA O14965 1/20 0.54
KIT P10721 1/20 0.54
FLT3 P36888 1/20 0.54
MAPK7 Q13164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23726903 0.89 ACHE (0.67) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL2912892 0.87 ACHE (0.65) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL2919932 0.87 ACHE (0.65) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL2916596 0.86 ACHE (0.64) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL906154 0.86 TLR9 (0.69) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL21415489 0.85 ACHE (0.61) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL2918088 0.83 TLR9 (0.76) ACHEBACE1PDGFRBPDGFRAAURKA
SCHEMBL30080209 0.82 TLR9 (0.65) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL23726540 0.82 TLR9 (0.65) ACHEBACE1PDGFRBPDGFRAENPP1
SCHEMBL23726390 0.82 ENPP1 (0.66) ACHEBACE1PDGFRBPDGFRAENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882717-B1 NITROGENOUS HETEROCYCLIC COMPOUNDS KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP disclosed
US-6750218-B2 INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS MILLENNIUMIUM PHARMACEUTICALS, INC. 2004-06-15 US disclosed
US-20030229077-A1 Nitrogen-containing heterocyclic compounds MATSUNO KENJI (JP) 2003-12-11 US disclosed
US-6472391-B2 INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. MILLENNIUM PHARMACEUTICALS, INC. 2002-10-29 US disclosed
US-20020068734-A1 Nitrogen-containing heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. 2002-06-06 US disclosed
US-6207667-B1 USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-03-27 US disclosed
US-6169088-B1 FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-01-02 US disclosed
EP-0882717-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229077-A1 Nitrogen-containing heterocyclic compounds ERBB4, NPR1, PDGFRB ACHE 4815/4885BACE1 4443/4885PDGFRB 3/4885
US-20020068734-A1 Nitrogen-containing heterocyclic compounds PDGFRB, MKI67, PDGFRA ACHE 4850/4885BACE1 4559/4885PDGFRB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.